Dual-pathway brightening, not single-step: Most body brighteners address only melanin distribution or production
However, diet [high intensity, non caloric] sweetener consumption is also correlated with metabolic syndrome , he argues, although he acknowledges that there is no proven causal link (proponents of diet sweeteners, meanwhile, argue that people with metabolic syndrome simply consume more diet drinks because they are watching their sugar/calorie intake)
Disadvantages of semaglutide include the fact that they are weekly injection (except the oral form, Rybelsus), higher costs, and side effects
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
Changes to your medication would need to go through your care team as part of an updated consultation
